Navigation Links
InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
Date:9/13/2010

  • 10:00 a.m. -- Percent predicted forced vital capacity is a reliable, valid, and responsive measure of clinical status in patients with idiopathic pulmonary fibrosis (Ron du Bois, M.D.)

  • About Pirfenidone

    InterMune has submitted a Marketing Authorization Application (MAA) seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, which was validated by the European Medicines Agency (EMA) effective March 24, 2010. Validation of the MAA by the EMA indicates that the application is complete and that the review process has begun.

    IPF is a rare and fatal lung disease that affects approximately 200,000 people in the United States and Europe combined. If approved by the EMA, pirfenidone would be the first medication to be made available to IPF patients in the European Union. Pirfenidone has been granted Orphan Drug designation in Europe.

    Preclinical and in-vitro evidence has shown that pirfenidone has both anti-fibrotic and anti-inflammatory effects. In February 2009, InterMune announced the results of the company's two global Phase 3 clinical trials evaluating pirfenidone for the treatment of IPF, known as the CAPACITY trials. Prior to the CAPACITY results, Shionogi & Co. Ltd (Shionogi) had presented data from a Phase 3 study conducted in Japan which demonstrated that pirfenidone reduced the decline in lung function and improved progression-free survival in patients with IPF. In this clinical study, pirfenidone was safe and generally well-tolerated, with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms. In October of 2008, pirfenidone was approved for use in IPF patients in Japan and is marketed as Pirespa® by Shionogi in that country.

    About InterMune

    InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. InterMune to Release Second Quarter Financial Results on July 27
    2. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
    3. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
    4. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
    5. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
    6. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
    7. InterMune to Present at Deutsche Bank Biotech Confab
    8. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
    9. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
    10. InterMune to Present at JMP Securities Conference
    11. InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/27/2015)... 2015 Biopharmaceutical Industry Leads Manufacturing Sector ... out on top as the country,s manufacturing leader in ...  from ndp│analytics. According to the  analysis , the industry ... the last decade, accounting for 27 percent of average ... A Short Video on Medicare Part D - ...
    (Date:3/27/2015)... Texas , March 27, 2015 The Temple ... in April to a 5,000-square-foot building at 1802 South First ... geographic area designated by the City of Temple ... Scott & White and the Central Texas Veterans Health Care ... and laboratory space to early stage biotechnology and life science ...
    (Date:3/27/2015)... 2015 A new report from Kalorama Information says ... – Chile , Colombia ... for IVD firms.  The healthcare research firm said that while ... for the Latin American continent with a population of over ... operations. However, the country,s regional economic clout does not necessarily ...
    Breaking Medicine Technology:Week in Review: The Latest from PhRMA 2Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4
    ... today announced that this year,s show has already eclipsed last ... Mark Alexay, its President. The annual chemistry and pharmaceutical ingredients ... from Contract Research and Manufacturing organizations. This ... Ocean Place Resort in Long Branch, NJ. ...
    ... WOODCLIFF LAKE, N. J., Aug. 4, 2011 ... calling for information on fragrance ingredients from the ... ketones. The Expert Panel will review this group ... are: (Logo: http://photos.prnewswire.com/prnh/20101215/DC17717LOGO) ...
    Cached Medicine Technology:2011 ChemOutsourcing Record Attendance Marks 5th Year of Uninterrupted Growth of Annual Pharmaceutical Ingredients Show 2Independent Expert Panel Calls for Information on Fragrance Ingredients Under Review 2
    (Date:3/29/2015)... March 29, 2015 Final Cut ... transition from Pixel Film Studios, entitled TranSports. , ... exclusively for Final Cut Pro X,” said Christiana Austin, ... the tools needed to effortlessly transition using this cool ... a new and uniquely styled transition pack for Final ...
    (Date:3/28/2015)... Tucson, AZ (PRWEB) March 28, 2015 Coffee ... could also help protect you from gum disease, researchers have ... protected against gum disease. , Coffee contains antioxidants. Antioxidants fight ... is the question researchers at Boston Univ. Henry M. Goldman ... published in the August 2014 issue of the Journal of ...
    (Date:3/28/2015)... MILAN (PRWEB) March 28, 2015 ... thought-leaders in the fields of osteoporosis, osteoarthritis and ... on Osteoporosis, it may be the first time ... educational research forum that the hot-button topic is ... Based on the well-accepted scientific principles of Wolff’s ...
    (Date:3/28/2015)... FL (PRWEB) March 28, 2015 ... conditions coverage is made available to all visitors who ... effective immediately. All members are encouraged to purchase the ... to avoid lack of proper coverage for pre-existing medical ... from one or two medical conditions with serious consequences ...
    (Date:3/28/2015)... March 28, 2015 One in three ... to research presented today at the American Orthopaedic Society ... study examined the long term success of surgery for ... examined survey data from 242 patients who underwent ACL ... P. Roe, MBBS, FRACS, from North Sydney Orthopaedic and ...
    Breaking Medicine News(10 mins):Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2
    ... a massive public awareness campaign on health and hygiene in ... UN Children's Fund (UNICEF) aims to educate more than two ... of the campaign will begin in Kabul on June 24, ... in following weeks. , ,Each phase lasts 20 days, ...
    ... wave therapy would cure ailments caused by irregular heartbeats, ... Electrophysiology said here today. // ,Speaking on ... Lifeline Hospital of the Dr K M Cherian Heart ... by irregular heartbeats, was prevalent among 10 per cent ...
    ... it is a dyslexic's mode of writing where letters in ... dyslexia, has a genetic component, according to German researchers. And ... treatment. , Dyslexia generally affects family groups. Scientists ... located the dyslexia gene, denoted as DCDC2, the presence of ...
    ... the Grampians Community Health Centre has made people to be ... ,Educating people about the adverse effects of some drugs ... center. ,Problems related to health, social, economical, ... drug misuse in every community. So, in the idea of ...
    ... some time now, concern has been raised by health authorities ... microbes to become drug resistant, especially to antibiotics //. ... majority of people are already harboring bacteria that are drugs ... of the mutated microorganisms to resist antibiotics is an ever-growing ...
    ... Boards and Primary Health Organisations, (PHOs), which faced difficulties late ... reaching an agreement on the extension of subsidies for ... GP patients, aged between 45 - 64 years, are expected ... long been at loggerheads over the conditions, with the ...
    Cached Medicine News:Health News:Drug - resistant microbes raise concerns 2
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: